Provided by Tiger Fintech (Singapore) Pte. Ltd.

Myriad Genetics

8.80
-0.0400-0.45%
Post-market: 8.53-0.2700-3.07%19:49 EDT
Volume:629.13K
Turnover:5.55M
Market Cap:803.52M
PE:-6.24
High:8.97
Open:8.67
Low:8.53
Close:8.84
Loading ...

BRIEF-Myriad Genetics Provides Update On Discussions With Unitedhealthcare Regarding Medical Policy For Pharmacogenetic Testing

Reuters
·
11 Dec 2024

Myriad Genetics Provides Update on Discussions With Unitedhealthcare Regarding Medical Policy for Pharmacogenetic Testing

THOMSON REUTERS
·
11 Dec 2024

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

GlobeNewswire
·
11 Dec 2024

BRIEF-Myriad Genetics Expands Board Of Directors With Election Of Mark S. Davis As New Board Member

Reuters
·
11 Dec 2024

Myriad Genetics : Approved an Increase in Size of Board From Eight to Nine Members

THOMSON REUTERS
·
11 Dec 2024

Myriad Genetics Expands Board of Directors With Election of Mark S. Davis as New Board Member

THOMSON REUTERS
·
11 Dec 2024

Press Release: Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

Dow Jones
·
11 Dec 2024

Myriad Genetics’ Portfolio Elevated by Updated Nccn Prostate Cancer Guidelines

THOMSON REUTERS
·
10 Dec 2024

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

GlobeNewswire
·
10 Dec 2024

New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?

Zacks
·
10 Dec 2024

Cautious Hold: Myriad Genetics Faces Growth Uncertainty Amid Reimbursement Challenges

TIPRANKS
·
10 Dec 2024

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

GlobeNewswire
·
10 Dec 2024

Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30

MT Newswires Live
·
09 Dec 2024

Nccn Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

THOMSON REUTERS
·
09 Dec 2024

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

GlobeNewswire
·
09 Dec 2024

Myriad Genetics Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
09 Dec 2024

Leerink downgrades Myriad Genetics on reimbursement, competitive headwinds

TIPRANKS
·
09 Dec 2024

Myriad Genetics Inc : Leerink Partners Cuts to Market Perform From Outperform

THOMSON REUTERS
·
09 Dec 2024

BRIEF-Myriad Genetics Says Settlement Was Approved By The Court In Myriad Genetics, Inc. Stockholder Derivative Litigation

Reuters
·
27 Nov 2024

Myriad Genetics Settles Shareholder Lawsuits with Reforms

TIPRANKS
·
27 Nov 2024